Specializing in an innovative mechanistic approach for treating older and frail patients with hematological malignancies
Specializing in an innovative mechanistic approach for treating older and frail patients with hematological malignancies
As the treatment landscape for hematological malignancies advances, especially with the growing prominence of cell and gene therapies, a substantial unmet need persists for innovative mechanisms of action (MoAs) and therapies that can address the unique challenges of treating elderly or frail patients. These patients are typically not suitable candidates for the more aggressive treatments typically reserved for "fit" patients. Our mission is to bridge this gap by delivering effective, accessible treatment options specifically designed to meet the needs of this underserved population in community settings.